| . | Using Opioids at Baseline (n = 116) . | Not Using Opioids at Baseline (n = 913) . | P . |
|---|---|---|---|
| Mean age in years at baseline (SD) | 57.4 (15.5) | 52.0 (17.0) | .001 |
| Female sex (%) | 63 (54.3) | 500 (54.8) | .93 |
| Married or co-habiting (%) | 80 (69.6) | 631 (69.6) | .99 |
| University graduate/professional (%) | 29 (25.4) | 358 (39.6) | .003 |
| Tobacco user (%) | 9 (7.8) | 58 (6.4) | .57 |
| Alcohol user (%) | 79 (69.3) | 668 (73.8) | .31 |
| IBD type (%) | .007 | ||
| CD | 66 (58.9) | 393 (43.3) | |
| UC | 40 (35.7) | 453 (49.9) | |
| IBD-U | 6 (5.4) | 61 (6.7) | |
| CD location (%) | .17 | ||
| Ileal | 25/66 (37.9) | 134/392 (34.2) | |
| Colonic | 13/66 (19.7) | 121/392 (30.9) | |
| Ileocolonic | 28/66 (42.4) | 137/392 (34.9) | |
| Stricturing CD (%) | 18/66 (27.3) | 112/393 (28.5) | .84 |
| Penetrating CD (%) | 12/66 (18.2) | 51/393 (13.0) | .26 |
| Perianal CD (%) | 8/66 (12.1) | 59/393 (15.0) | .54 |
| Previous intestinal resection (%) | 38 (33.9) | 132 (14.5) | <.001 |
| UC extent (%) | .49 | ||
| Proctitis | 11/40 (27.5) | 139/447 (31.1) | |
| Left-sided | 13/40 (32.5) | 170/447 (38.0) | |
| Extensive | 16/40 (40.0) | 138/447 (30.9) | |
| Current 5-aminosalicylate use (%) | 49 (43.8) | 499 (55.0) | .024 |
| Current immunomodulator use (%) | 34 (30.4) | 252 (27.8) | .57 |
| Current biologic use (%) | 29 (25.9) | 191 (21.1) | .53 |
| Current glucocorticosteroid use (%) | 8 (7.1) | 25 (2.8) | .013 |
| Current antidepressant use (%) | 44 (37.9) | 126 (13.8) | <.001 |
| Diagnosed with IBD in the last 12 months (%) | 9 (7.8) | 64 (7.1) | .78 |
| Self-reported current flare at baseline (%) | 39 (33.9) | 151 (16.6) | <.001 |
| Active disease on HBI or SCCAI at baseline (%) | 69 (61.1) | 304 (33.8) | <.001 |
| HADS-anxiety categories at baseline (%) | .002 | ||
| Normal | 48 (42.1) | 525 (59.0) | |
| Borderline abnormal | 30 (26.3) | 186 (20.9) | |
| Abnormal | 36 (31.6) | 179 (20.1) | |
| HADS-depression categories at baseline (%) | <.001 | ||
| Normal | 62 (53.9) | 701 (78.1) | |
| Borderline abnormal | 24 (20.9) | 124 (13.8) | |
| Abnormal | 29 (25.2) | 73 (8.1) | |
| PHQ-12 somatoform symptom-reporting categories at baseline (%) | <.001 | ||
| Minimal | 8 (7.9) | 263 (31.3) | |
| Low | 23 (22.8) | 321 (38.2) | |
| Medium | 46 (45.5) | 188 (22.5) | |
| High | 24 (23.8) | 68 (8.1) | |
| Rome IV IBS-type symptoms at baseline (%) | 30 (29.7) | 135 (15.5) | .001 |
| Mean SIBDQ score at baseline (SD) | 42.2 (14.4) | 51.8 (12.4) | <.001 |
| . | Using Opioids at Baseline (n = 116) . | Not Using Opioids at Baseline (n = 913) . | P . |
|---|---|---|---|
| Mean age in years at baseline (SD) | 57.4 (15.5) | 52.0 (17.0) | .001 |
| Female sex (%) | 63 (54.3) | 500 (54.8) | .93 |
| Married or co-habiting (%) | 80 (69.6) | 631 (69.6) | .99 |
| University graduate/professional (%) | 29 (25.4) | 358 (39.6) | .003 |
| Tobacco user (%) | 9 (7.8) | 58 (6.4) | .57 |
| Alcohol user (%) | 79 (69.3) | 668 (73.8) | .31 |
| IBD type (%) | .007 | ||
| CD | 66 (58.9) | 393 (43.3) | |
| UC | 40 (35.7) | 453 (49.9) | |
| IBD-U | 6 (5.4) | 61 (6.7) | |
| CD location (%) | .17 | ||
| Ileal | 25/66 (37.9) | 134/392 (34.2) | |
| Colonic | 13/66 (19.7) | 121/392 (30.9) | |
| Ileocolonic | 28/66 (42.4) | 137/392 (34.9) | |
| Stricturing CD (%) | 18/66 (27.3) | 112/393 (28.5) | .84 |
| Penetrating CD (%) | 12/66 (18.2) | 51/393 (13.0) | .26 |
| Perianal CD (%) | 8/66 (12.1) | 59/393 (15.0) | .54 |
| Previous intestinal resection (%) | 38 (33.9) | 132 (14.5) | <.001 |
| UC extent (%) | .49 | ||
| Proctitis | 11/40 (27.5) | 139/447 (31.1) | |
| Left-sided | 13/40 (32.5) | 170/447 (38.0) | |
| Extensive | 16/40 (40.0) | 138/447 (30.9) | |
| Current 5-aminosalicylate use (%) | 49 (43.8) | 499 (55.0) | .024 |
| Current immunomodulator use (%) | 34 (30.4) | 252 (27.8) | .57 |
| Current biologic use (%) | 29 (25.9) | 191 (21.1) | .53 |
| Current glucocorticosteroid use (%) | 8 (7.1) | 25 (2.8) | .013 |
| Current antidepressant use (%) | 44 (37.9) | 126 (13.8) | <.001 |
| Diagnosed with IBD in the last 12 months (%) | 9 (7.8) | 64 (7.1) | .78 |
| Self-reported current flare at baseline (%) | 39 (33.9) | 151 (16.6) | <.001 |
| Active disease on HBI or SCCAI at baseline (%) | 69 (61.1) | 304 (33.8) | <.001 |
| HADS-anxiety categories at baseline (%) | .002 | ||
| Normal | 48 (42.1) | 525 (59.0) | |
| Borderline abnormal | 30 (26.3) | 186 (20.9) | |
| Abnormal | 36 (31.6) | 179 (20.1) | |
| HADS-depression categories at baseline (%) | <.001 | ||
| Normal | 62 (53.9) | 701 (78.1) | |
| Borderline abnormal | 24 (20.9) | 124 (13.8) | |
| Abnormal | 29 (25.2) | 73 (8.1) | |
| PHQ-12 somatoform symptom-reporting categories at baseline (%) | <.001 | ||
| Minimal | 8 (7.9) | 263 (31.3) | |
| Low | 23 (22.8) | 321 (38.2) | |
| Medium | 46 (45.5) | 188 (22.5) | |
| High | 24 (23.8) | 68 (8.1) | |
| Rome IV IBS-type symptoms at baseline (%) | 30 (29.7) | 135 (15.5) | .001 |
| Mean SIBDQ score at baseline (SD) | 42.2 (14.4) | 51.8 (12.4) | <.001 |
aIndependent samples tvtest for comparison of normally distributed continuous data and χ2 for comparison of categorical data between groups.
| . | Using Opioids at Baseline (n = 116) . | Not Using Opioids at Baseline (n = 913) . | P . |
|---|---|---|---|
| Mean age in years at baseline (SD) | 57.4 (15.5) | 52.0 (17.0) | .001 |
| Female sex (%) | 63 (54.3) | 500 (54.8) | .93 |
| Married or co-habiting (%) | 80 (69.6) | 631 (69.6) | .99 |
| University graduate/professional (%) | 29 (25.4) | 358 (39.6) | .003 |
| Tobacco user (%) | 9 (7.8) | 58 (6.4) | .57 |
| Alcohol user (%) | 79 (69.3) | 668 (73.8) | .31 |
| IBD type (%) | .007 | ||
| CD | 66 (58.9) | 393 (43.3) | |
| UC | 40 (35.7) | 453 (49.9) | |
| IBD-U | 6 (5.4) | 61 (6.7) | |
| CD location (%) | .17 | ||
| Ileal | 25/66 (37.9) | 134/392 (34.2) | |
| Colonic | 13/66 (19.7) | 121/392 (30.9) | |
| Ileocolonic | 28/66 (42.4) | 137/392 (34.9) | |
| Stricturing CD (%) | 18/66 (27.3) | 112/393 (28.5) | .84 |
| Penetrating CD (%) | 12/66 (18.2) | 51/393 (13.0) | .26 |
| Perianal CD (%) | 8/66 (12.1) | 59/393 (15.0) | .54 |
| Previous intestinal resection (%) | 38 (33.9) | 132 (14.5) | <.001 |
| UC extent (%) | .49 | ||
| Proctitis | 11/40 (27.5) | 139/447 (31.1) | |
| Left-sided | 13/40 (32.5) | 170/447 (38.0) | |
| Extensive | 16/40 (40.0) | 138/447 (30.9) | |
| Current 5-aminosalicylate use (%) | 49 (43.8) | 499 (55.0) | .024 |
| Current immunomodulator use (%) | 34 (30.4) | 252 (27.8) | .57 |
| Current biologic use (%) | 29 (25.9) | 191 (21.1) | .53 |
| Current glucocorticosteroid use (%) | 8 (7.1) | 25 (2.8) | .013 |
| Current antidepressant use (%) | 44 (37.9) | 126 (13.8) | <.001 |
| Diagnosed with IBD in the last 12 months (%) | 9 (7.8) | 64 (7.1) | .78 |
| Self-reported current flare at baseline (%) | 39 (33.9) | 151 (16.6) | <.001 |
| Active disease on HBI or SCCAI at baseline (%) | 69 (61.1) | 304 (33.8) | <.001 |
| HADS-anxiety categories at baseline (%) | .002 | ||
| Normal | 48 (42.1) | 525 (59.0) | |
| Borderline abnormal | 30 (26.3) | 186 (20.9) | |
| Abnormal | 36 (31.6) | 179 (20.1) | |
| HADS-depression categories at baseline (%) | <.001 | ||
| Normal | 62 (53.9) | 701 (78.1) | |
| Borderline abnormal | 24 (20.9) | 124 (13.8) | |
| Abnormal | 29 (25.2) | 73 (8.1) | |
| PHQ-12 somatoform symptom-reporting categories at baseline (%) | <.001 | ||
| Minimal | 8 (7.9) | 263 (31.3) | |
| Low | 23 (22.8) | 321 (38.2) | |
| Medium | 46 (45.5) | 188 (22.5) | |
| High | 24 (23.8) | 68 (8.1) | |
| Rome IV IBS-type symptoms at baseline (%) | 30 (29.7) | 135 (15.5) | .001 |
| Mean SIBDQ score at baseline (SD) | 42.2 (14.4) | 51.8 (12.4) | <.001 |
| . | Using Opioids at Baseline (n = 116) . | Not Using Opioids at Baseline (n = 913) . | P . |
|---|---|---|---|
| Mean age in years at baseline (SD) | 57.4 (15.5) | 52.0 (17.0) | .001 |
| Female sex (%) | 63 (54.3) | 500 (54.8) | .93 |
| Married or co-habiting (%) | 80 (69.6) | 631 (69.6) | .99 |
| University graduate/professional (%) | 29 (25.4) | 358 (39.6) | .003 |
| Tobacco user (%) | 9 (7.8) | 58 (6.4) | .57 |
| Alcohol user (%) | 79 (69.3) | 668 (73.8) | .31 |
| IBD type (%) | .007 | ||
| CD | 66 (58.9) | 393 (43.3) | |
| UC | 40 (35.7) | 453 (49.9) | |
| IBD-U | 6 (5.4) | 61 (6.7) | |
| CD location (%) | .17 | ||
| Ileal | 25/66 (37.9) | 134/392 (34.2) | |
| Colonic | 13/66 (19.7) | 121/392 (30.9) | |
| Ileocolonic | 28/66 (42.4) | 137/392 (34.9) | |
| Stricturing CD (%) | 18/66 (27.3) | 112/393 (28.5) | .84 |
| Penetrating CD (%) | 12/66 (18.2) | 51/393 (13.0) | .26 |
| Perianal CD (%) | 8/66 (12.1) | 59/393 (15.0) | .54 |
| Previous intestinal resection (%) | 38 (33.9) | 132 (14.5) | <.001 |
| UC extent (%) | .49 | ||
| Proctitis | 11/40 (27.5) | 139/447 (31.1) | |
| Left-sided | 13/40 (32.5) | 170/447 (38.0) | |
| Extensive | 16/40 (40.0) | 138/447 (30.9) | |
| Current 5-aminosalicylate use (%) | 49 (43.8) | 499 (55.0) | .024 |
| Current immunomodulator use (%) | 34 (30.4) | 252 (27.8) | .57 |
| Current biologic use (%) | 29 (25.9) | 191 (21.1) | .53 |
| Current glucocorticosteroid use (%) | 8 (7.1) | 25 (2.8) | .013 |
| Current antidepressant use (%) | 44 (37.9) | 126 (13.8) | <.001 |
| Diagnosed with IBD in the last 12 months (%) | 9 (7.8) | 64 (7.1) | .78 |
| Self-reported current flare at baseline (%) | 39 (33.9) | 151 (16.6) | <.001 |
| Active disease on HBI or SCCAI at baseline (%) | 69 (61.1) | 304 (33.8) | <.001 |
| HADS-anxiety categories at baseline (%) | .002 | ||
| Normal | 48 (42.1) | 525 (59.0) | |
| Borderline abnormal | 30 (26.3) | 186 (20.9) | |
| Abnormal | 36 (31.6) | 179 (20.1) | |
| HADS-depression categories at baseline (%) | <.001 | ||
| Normal | 62 (53.9) | 701 (78.1) | |
| Borderline abnormal | 24 (20.9) | 124 (13.8) | |
| Abnormal | 29 (25.2) | 73 (8.1) | |
| PHQ-12 somatoform symptom-reporting categories at baseline (%) | <.001 | ||
| Minimal | 8 (7.9) | 263 (31.3) | |
| Low | 23 (22.8) | 321 (38.2) | |
| Medium | 46 (45.5) | 188 (22.5) | |
| High | 24 (23.8) | 68 (8.1) | |
| Rome IV IBS-type symptoms at baseline (%) | 30 (29.7) | 135 (15.5) | .001 |
| Mean SIBDQ score at baseline (SD) | 42.2 (14.4) | 51.8 (12.4) | <.001 |
aIndependent samples tvtest for comparison of normally distributed continuous data and χ2 for comparison of categorical data between groups.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
